US20130267552A1 - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy Download PDF

Info

Publication number
US20130267552A1
US20130267552A1 US13/856,254 US201313856254A US2013267552A1 US 20130267552 A1 US20130267552 A1 US 20130267552A1 US 201313856254 A US201313856254 A US 201313856254A US 2013267552 A1 US2013267552 A1 US 2013267552A1
Authority
US
United States
Prior art keywords
tetrabenazine
pridopidine
pharmaceutically acceptable
acceptable salt
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/856,254
Other languages
English (en)
Inventor
Ross Nicholas Waters
Eva Susanna Holm Waters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
NTG Nordic Transport Group AS
Original Assignee
Ivax International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax International GmbH filed Critical Ivax International GmbH
Priority to US13/856,254 priority Critical patent/US20130267552A1/en
Assigned to NEUROSEARCH A/S reassignment NEUROSEARCH A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOLM WATERS, EVA SUSANNA, WATERS, ROSS NICHOLAS
Assigned to IVAX International GmbH reassignment IVAX International GmbH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEUROSEARCH A/S
Publication of US20130267552A1 publication Critical patent/US20130267552A1/en
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: IVAX International GmbH
Priority to US15/612,779 priority patent/US20170266170A1/en
Priority to US16/203,182 priority patent/US11207308B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Pridopidine i.e. 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine, is a drug substance currently in clinical development for the treatment of Huntington's disease. This compound was first described in WO 01/46145.
  • Pridopidine is a dopaminergic stabilizer that displays competitive dopamine D2 receptor antagonism with fast dissociation kinetics (Dyhring, 2010).
  • Dyhring, 2010 In vivo Pridopidine increases turnover and release of dopamine in the striatum and in the frontal cortex (Poten, 2010; Pettersson 2010).
  • Behavioural effects include antagonism of psychostimulant induced hyperactivity, suggesting antipsychotic properties, but no inhibitory effects on spontaneous locomotor activity (Ponten, 2010; Natesan 2006; Nilsson, 2004).
  • Tetrabenzine i.e. (SS,RR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one
  • FDA Label for XENAZINE Tetrabenzine
  • Tetrabenazine is an inhibitor of the vesicular monoamine transporter type 2 (VMAT), that blocks the vesicular storage of monoamine neurotransmitters in the brain, thereby leading to reduced synaptic release of dopamine, serotonin and norepinephrin (Paleacu, 2007).
  • This reduction of monoaminergic neurotransmission is associated with suppression of e.g. dopamine dependent functions, including movement and reward.
  • the suppression of movements is used therapeutically to ameliorate involuntary movements in e.g. Huntington's disease, tardive dyskinesia, and Tourette's disease.
  • Treatment with Tetrabenazine is associated with severe side effects.
  • Such side effects include parkinsonism, i.e. rigidity and impaired motor function, depression, and impaired functional capacity.
  • Involuntary movements such as chorea and dyskinesia, occurring as part of the clinical manifestations of e.g. Huntington's disease, are believed to be related to impaired activity in the indirect cortico-striato-thalamic pathway.
  • Tetrabenazine the beneficial effects of Tetrabenazine on such involuntary movements are due to a decreased tone at dopamine D2 receptors on medium spiny neurons of the indirect pathway, occurring as a consequence of the reduction in dopamine transmission engendered by Tetrabenazine.
  • the decreased dopamine D2 receptor tone leads to a reduced inhibition of these medium spiny neurons, and therefore, an increased activity of the indirect pathway, and improved suppression of involuntary movements.
  • dopamine D2 antagonists are also frequently used to alleviate chorea in HD (Steward 2001).
  • Pridopidine is capable of reversing the behavioural inhibition caused by Tetrabenazine, while maintaining the primary pharmacological effect of Pridopidine, i.e. dopamine D2 receptor blockade.
  • the subject invention provides a method of treating a subject afflicted with a movement disorder comprising periodically administering to the subject an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, and an amount of Pridopidine or a pharmaceutically acceptable salt thereof.
  • the subject invention also provides a method of treating a subject afflicted with obesity, an obesity associated disorder, or a cardiovascular side effect of Pridopidine comprising administering to the subject an amount of Pridopidine or a pharmaceutically acceptable salt thereof, and an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof.
  • the subject invention also provides a method of reducing or preventing one or more side effects of periodically administering of an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof to a subject, comprising periodically administering to the subject an amount of Pridopidine or a pharmaceutically acceptable salt thereof.
  • the subject invention also provides a package comprising:
  • a) a first pharmaceutical composition comprising an amount of Tetrabenazine or a pharmaceutically ac-ceptable salt thereof and a pharmaceutically ac-ceptable carrier;
  • the subject invention also provides Pridopidine or pharmaceutically acceptable salt thereof for use as an add-on therapy of or in combination with Tetrabenazine or pharmaceutical acceptable salt thereof in treating a subject afflicted with a movement disorder.
  • the subject invention also provides a pharmaceutical composition comprising an amount of Tetrabenazine or pharmaceutically acceptable salt thereof, an amount of Pridopidine or pharmaceutical acceptable salt thereof, and at least one pharmaceutical acceptable carrier.
  • the subject invention also provides the use of:
  • the subject invention also provides a pharmaceutical composition comprising an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof for use in treating a subject afflicted with a movement disorder, in combination with an amount of Pridopidine or pharmaceutically acceptable salt thereof, by periodically administering to the subject the pharmaceutical composition and the amount of Pridopidine or pharmaceutically acceptable salt thereof.
  • the subject invention also provides a pharmaceutical composition comprising an amount of Pridopidine or pharmaceutically acceptable salt thereof for use treating a subject afflicted with a movement disorder, in combination with an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, by periodically administering to the subject the pharmaceutical composition and the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof.
  • the subject invention also provides Tetrabenazine or a pharmaceutically acceptable salt thereof and Pridopidine or a pharmaceutically acceptable salt thereof for the treatment of a subject afflicted with a movement disorder, wherein the Tetrabenazine or a pharmaceutically acceptable salt thereof and the Pridopidine or a pharmaceutically acceptable salt thereof are administered simultaneously, separately or sequentially.
  • the subject invention also provides a product containing an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof and an amount of Pridopidine or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use in treating a subject afflicted with a movement disorder.
  • the subject invention also provides a method of treating a subject afflicted with obesity, an obesity associated disorder or a cardiovascular side effect of Pridopidine comprising administering to the subject a combination of a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to treat the subject.
  • the subject invention also provides a combination of Pridopidine, or a pharmaceutically acceptable salt thereof; and Tetrabenazine, or a pharmaceutically acceptable salt thereof; for the treatment, prevention or alleviation of obesity, or an obesity associated disorder, and for treatment, prevention or alleviation of the cardiovascular side effects of Pridopidine, in a mammal, including a human.
  • the invention provides a combination of Pridopidine, or a pharmaceutically acceptable salt thereof, and Tetrabenazine, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment, prevention or alleviation of a movement disorder.
  • the invention provides a combination of Pridopidine, or a pharmaceutically acceptable salt thereof, and Tetrabenazine, or a pharmaceutically acceptable salt thereof, for use as a medicament.
  • the invention provides a combination of Pridopidine, or a pharmaceutically acceptable salt thereof; and Tetrabenazine, or a pharmaceutically acceptable salt thereof; for the treatment, prevention or alleviation of obesity, or an obesity associated disorder, and for treatment, prevention or alleviation of the cardiovascular side effects of Pridopidine, in a mammal, including a human.
  • the invention relates to the use of a combination of Pridopidine, or a pharmaceutically acceptable salt thereof; and Tetrabenazine, or a pharmaceutically acceptable salt thereof; for the manufacture of a medicament for the treatment, prevention or alleviation of a movement disorder of a mammal, including a human.
  • the invention provides a pharmaceutical composition comprising Pridopidine, or a pharmaceutically acceptable salt thereof, for use in a combination therapy together with a pharmaceutical composition comprising Tetrabenazine, or a pharmaceutically acceptable salt thereof, for the treatment, prevention or alleviation of a movement disorder.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Pridopidine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine, or a pharmaceutically acceptable salt thereof, together with one or more adjuvants, excipients, carriers and/or diluents.
  • the invention provides a method of treatment, prevention or alleviation of a movement disorder in a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of Pridopidine, or a pharmaceutically acceptable salt thereof; in a combination therapy with Tetrabenazine, or a pharmaceutically acceptable salt thereof.
  • the invention provides a kit of parts comprising at least two separate unit dosage forms (A) and (B), wherein (A) comprises Pridopidine, or a pharmaceutically acceptable salt thereof; and (B) comprises Tetrabenazine, or a pharmaceutically acceptable salt thereof; and optionally (C) instructions for the simultaneous, sequential or separate administration of the Pridopidine of (A) and the Tetrabenazine of (B), to a patient in need thereof.
  • the invention provides an article of manufacture, comprising (A) a first pharmaceutical dosage form comprising Pridopidine, or a pharmaceutically acceptable salt thereof; and (B) a second pharmaceutical dosage form comprising Tetrabenazine, or a pharmaceutically acceptable salt thereof; wherein the article contains first and second pharmaceutical dosage forms.
  • the invention provides a method of treating a subject afflicted with a movement disorder comprising administering to the subject a combination of a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to treat the human patient.
  • the invention provides a method of treating a mammal, including a human, afflicted with an obesity, or an obesity associated disorder or of the cardiovascular side effects of Pridopidine comprising administering to the subject a combination of a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to treat the mammal.
  • LMA locomotor activity
  • Vehicle Glucose 5.5% v/w
  • Tetrabenazine tested at three doses (0.37; 0.64 and 1.1 ⁇ mol/kg). All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • Vehicle saline; NaCl 0.9% v/w
  • Pridopidine tested at three doses (11; 33 and 100 ⁇ mol/kg). All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • Vehicle saline; NaCl 0.9% v/w
  • Pridopidine tested at three doses (11; 33 and 100 ⁇ mol/kg). All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • Vehicle Glucose 5.5% v/w
  • Haloperidol tested at four doses (0.04; 0.12; 0.37 and 1.1 ⁇ mol/kg). All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • FIG. 11 Spontaneous locomotor activity expressed as a percentage of the mean control group value for Tetrabenazine+Pridopidine. Activity is shown by dose for each recorded time period.
  • FIG. 12 The effect of Pridopidine on Tetrabenazine induced striatal dopamine increase.
  • the treatment groups consisted of Vehicle 1:1 (saline; NaCl 0.9% v/w+5.5% glukos with a few drops of HAc)
  • the second group consisted of a single dose of Tetrabenazine (0.64 mg/kg)
  • the third and fourth groups consisted of Pridopidine (NS30016) tested in two doses (33 and 100 ⁇ mol/kg together with Tetrabenazine in one dose (0.64 mg/kg). All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • region striatal arc (arcS) or frontal cortex arc (arcF)
  • the treatment groups consisted of Vehicle 1:1 (saline; NaCl 0.9% v/w+5.5% glukos with a few drops of HAc) the second group consisted of a single dose of Tetrabenazine (0.64 mg/kg) and the third and fourth groups consisted of Pridopidine tested in two doses (33 and 100 ⁇ mol/kg together with Tetrabenazine in one dose (0.64 mg/kg All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • FIG. 15 The effect of Haloperidol on Tetrabenazine induced striatal dopamine increase.
  • the treatment groups consisted of Vehicle 1:1 (saline; NaCl 0.9% v/w+5.5% glukos with a few drops of HAc)
  • the second group consisted of a single dose of Tetrabenazine (0.64 mg/kg)
  • the third and fourth groups consisted of Haloperidol tested in two doses (0.04 and 0.12 mg/kg together with Tetrabenazine in one dose (0.64 mg/kg). All compounds were injected s.c. four minutes before start of locomotor activity recording at a volume of 5 ml/kg.
  • the present invention relates to a combination therapy using Pridopidine and Tetrabenazine for the treatment, prevention or alleviation of a movement disorder.
  • Pridopidine reversed the behavioural inhibition caused by Tetrabenazine.
  • This behavioural inhibition is a preclinical correlate of some troublesome dopamine related side effects limiting the use of Tetrabenazine, especially the clear-cut motor side effects, such as parkinsonism, i.e. reduced motility, but also possibly depressed mood.
  • this reversal of the behavioural inhibition induced by Tetrabenazine is not to be expected from a compound acting as a pure antagonist at dopamine D2 receptors, such as Pridopidine, and was not observed in a similar study performed with the dopamine D2 antagonist Haloperidol. Rather, co-treatment with Haloperidol further reduced locomotor activity.
  • the subject invention provides a method of treating a subject afflicted with a movement disorder comprising periodically administering to the subject an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, and an amount of Pridopidine or a pharmaceutically acceptable salt thereof.
  • the subject invention also provides a method of treating a subject afflicted with obesity, an obesity associated disorder, or a cardiovascular side effect of Pridopidine comprising administering to the subject an amount of Pridopidine or a pharmaceutically acceptable salt thereof, and an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof.
  • the amounts when taken together are more effective to treat the subject than when each agent at the same amount is administered alone.
  • either the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof when taken alone, and the amount of Pridopidine or a pharmaceutically acceptable salt thereof when taken alone, or each such amount when taken alone is not effective to treat the subject.
  • the subject invention also provides a method of reducing or preventing one or more side effects of periodically administering of an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof to a subject, comprising periodically administering to the subject an amount of Pridopidine or a pharmaceutically acceptable salt thereof.
  • the one or more side effects are selected from depression, suicidality, akathisia, restlessness, agitation, parkinsonism, sedation, somnolence, and dysphagia.
  • the side effect is parkinsonism.
  • the subject is afflicted with a movement disorder.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is administered via oral administration.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is administered daily.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is administered twice daily.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is administered three times daily.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is 0.05 mg/kg per day to 0.20 mg/kg per day.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is 5-100 mg/day.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof is 12.5 mg/day, 25 mg/day, 37.5 mg/day, 50 mg/day, 75 mg/day, or 100 mg/day.
  • the amount of Pridopidine or a pharmaceutically acceptable salt thereof is administered via oral administration.
  • the amount of Pridopidine or a pharmaceutically acceptable salt thereof is administered daily.
  • the amount of Pridopidine or a pharmaceutically acceptable salt thereof is administered twice daily.
  • the amount of Pridopidine or a pharmaceutically acceptable salt thereof is 1.5 ⁇ mol/kg per day to 20 ⁇ mol/kg per day.
  • the amount of Pridopidine or a pharmaceutically acceptable salt thereof is 10-100 mg/day.
  • the amount of Pridopidine or a pharmaceutically acceptable salt thereof is 10 mg/day, 20 mg/day, 22.5 mg/day, 45 mg/day, or 90 mg/day.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof and the amount of Pridopidine or a pharmaceutically acceptable salt thereof is effective to alleviate a symptom of the movement disorder.
  • the symptom is chorea.
  • the subject is receiving Tetrabenazine therapy prior to initiating administration of Pridopidine or a pharmaceutically acceptable salt thereof.
  • the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof and the amount of Pridopidine or a pharmaceutically acceptable salt thereof are administered simultaneously.
  • the subject is a human patient.
  • the subject invention also provides a package comprising:
  • a) a first pharmaceutical composition comprising an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier;
  • the package is for use in treating a subject afflicted with a movement disorder.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the subject invention also provides Pridopidine or pharmaceutically acceptable salt thereof for use as an add-on therapy of or in combination with Tetrabenazine or pharmaceutical acceptable salt thereof in treating a subject afflicted with a movement disorder.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the subject invention also provides a pharmaceutical composition comprising an amount of Tetrabenazine or pharmaceutically acceptable salt thereof, an amount of Pridopidine or pharmaceutical acceptable salt thereof, and at least one pharmaceutical acceptable carrier.
  • the amount of Tetrabenazine or pharmaceutically acceptable salt thereof is 5-100 mg. In an embodiment, the amount of Tetrabenazine or pharmaceutically acceptable salt thereof is 5 mg, 6.25 mg, 12.5 mg, 25 mg, 37.5 mg, 50 mg, 75 mg, or 100 mg.
  • the amount of Pridopidine or pharmaceutical acceptable salt thereof is 10-100 mg.
  • the amount of Pridopidine or pharmaceutical acceptable salt thereof is 10 mg, 22.5 mg, 45 mg, or 90 mg.
  • the pharmaceutical composition is for use in treating a subject afflicted with a movement disorder.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the pharmaceutical composition is for use in treating, preventing or alleviating a subject afflicted with obesity, an obesity associated disorder, or a cardiovascular side effects of Pridopidine.
  • the subject invention also provides the use of:
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the subject invention also provides a pharmaceutical composition comprising an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof for use in treating a subject afflicted with a movement disorder, in combination with an amount of Pridopidine or pharmaceutically acceptable salt thereof, by periodically administering to the subject the pharmaceutical composition and the amount of Pridopidine or pharmaceutically acceptable salt thereof.
  • the subject invention also provides a pharmaceutical composition comprising an amount of Pridopidine or pharmaceutically acceptable salt thereof for use treating a subject afflicted with a movement disorder, in combination with an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, by periodically administering to the subject the pharmaceutical composition and the amount of Tetrabenazine or a pharmaceutically acceptable salt thereof.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the subject invention also provides Tetrabenazine or a pharmaceutically acceptable salt thereof and Pridopidine or a pharmaceutically acceptable salt thereof for the treatment of a subject afflicted with a movement disorder, wherein the Tetrabenazine or a pharmaceutically acceptable salt thereof and the Pridopidine or a pharmaceutically acceptable salt thereof are administered simultaneously, separately or sequentially.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the subject invention also provides a product containing an amount of Tetrabenazine or a pharmaceutically acceptable salt thereof and an amount of Pridopidine or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use in treating a subject afflicted with a movement disorder.
  • the movement disorder is Huntington's disease, Tourette's syndrome, or tardive dyskinesia.
  • the subject invention also provides a method of treating a subject afflicted with obesity, an obesity associated disorder or a cardiovascular side effect of Pridopidine comprising administering to the subject a combination of a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to treat the subject.
  • the subject is a human patient.
  • the subject invention also provides a combination of Pridopidine, or a pharmaceutically acceptable salt thereof; and Tetrabenazine, or a pharmaceutically acceptable salt thereof; for the treatment, prevention or alleviation of obesity, or an obesity associated disorder, and for treatment, prevention or alleviation of the cardiovascular side effects of Pridopidine, in a mammal, including a human.
  • the present invention relates to a combination therapy in which a pharmaceutically effective amount of Pridopidine, or a pharmaceutically acceptable salt thereof, is administered together with a therapeutically effective amount of Tetrabenazine, or a pharmaceutically acceptable salt thereof, for the treatment, prevention or alleviation of a movement disorder.
  • the hyperkinetic movement disorder is an involuntary hyperkinetic movement disorder arising from Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia, and in particular an involuntary hyperkinetic movement disorder arising from Huntington's disease.
  • the invention provides a combination of Pridopidine, or a pharmaceutically acceptable salt thereof, and Tetrabenazine, or a pharmaceutically acceptable salt thereof, for use as a medicament.
  • the invention relates to the use of a combination of
  • Tetrabenzine or a pharmaceutically acceptable salt thereof; for the manufacture of a medicament for the treatment, prevention or alleviation of a movement disorder of a mammal, including a human.
  • the invention provides pharmaceutical compositions comprising Pridopidine, or a pharmaceutically acceptable salt thereof, for use in a combination therapy together with Tetrabenazine, or a pharmaceutically acceptable salt thereof, for the treatment, prevention or alleviation of a hyperkinetic movement disorder.
  • the invention provides a method for the treatment, prevention or alleviation of a hyperkinetic movement disorder in a living animal body, which method comprises the step of administering to such animal bodies in need thereof, a therapeutically effective amount of Pridopidine, or a pharmaceutically acceptable salt thereof; in a combination therapy with Tetrabenazine, or a pharmaceutically acceptable salt thereof.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Pridopidine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine, or a pharmaceutically acceptable salt thereof.
  • the invention provides for a kit of parts comprising at least two separate unit dosage forms (A) and (B), wherein (A) comprises Pridopidine, or a pharmaceutically acceptable salt thereof; and (B) comprises Tetrabenazine, or a pharmaceutically acceptable salt thereof, and optionally (C), instructions for the simultaneous, sequential or separate administration of the Pridopidine of (A) and the Tetrabenazine of (B), to a patient in need thereof.
  • the invention provides an article of manufacture, comprising (A) a first pharmaceutical dosage form comprising Pridopidine, or a pharmaceutically acceptable salt thereof; and (B) a second pharmaceutical dosage form comprising Tetrabenazine, or a pharmaceutically acceptable salt thereof; wherein the article contains first and second pharmaceutical dosage forms.
  • the invention provides a method of treating a subject afflicted with a movement disorder comprising administering to the subject a combination of a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to treat the human patient.
  • the movement disorder is an involuntary hyperkinetic movement disorder arising from Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.
  • the movement disorder is an involuntary hyperkinetic movement disorder arising from Huntington's disease
  • the invention provides a method of treating a mammal, including a human, afflicted with an obesity, or an obesity associated disorder or of the cardiovascular side effects of Pridopidine comprising administering to the subject a combination of a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of Tetrabenazine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to treat a mammal.
  • the therapeutically effective amount of Pridopidine or the pharmaceutically acceptable salt thereof, and the therapeutically effective amount of Tetrabenazine or the pharmaceutically acceptable salt thereof are administered orally.
  • the therapeutically effective amount of Pridopidine or the pharmaceutically acceptable salt thereof, and the therapeutically effective amount of Tetrabenazine or the pharmaceutically acceptable salt thereof are administered intravenously.
  • the therapeutically effective amount of Pridopidine or the pharmaceutically acceptable salt thereof, and the therapeutically effective amount of Tetrabenazine or the pharmaceutically acceptable salt thereof are administered by direct penetration of the drug through the stratum corneum.
  • the Pridopidine containing medicament may be applied simultaneously with Tetrabenazine, in a sequential manner, or by separate administration.
  • Pridopidine is given at the same time as Tetrabenazine.
  • Pridopidine may be used (co-administered with Tetrabenazine) in a therapeutically effective amount in the range of about 0.01-1000 mg API daily, more preferred in the range of about 1-500 mg API daily, even more preferred in the range of about 10-200 mg API daily.
  • Tetrabenazine may be used (co-administered with Pridopidine) in a therapeutically effective amount in the range of about 0.01-1000 mg API daily, more preferred in the range of about 1-500 mg API daily, even more preferred in the range of about 10-200 mg API daily.
  • Pridopidine and Tetrabenazine may be co-administered by any conventional route.
  • Pridopidine and Tetrabenazine are administered either orally, intravenously, intravascularly, intraperitoneally, sub-cutaneously, intramuscularly, inhalatively, topically, by patch, or by suppository.
  • Pridopidine and Tetrabenazine are administered orally (p.o.).
  • Pridopidine and Tetrabenazine are administered intravenously (i.v.).
  • Pridopidine and Tetrabenazine are administered by subcutaneous (s.c.) injection.
  • the active compounds for use according to the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phos-phate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fume-rate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like.
  • Such salts may be formed by procedures well known and described in the art.
  • the compounds for use according to the invention may be administered in the form of the raw compound, it is preferred to introduce the active ingredients, optionally in the form of physiologically acceptable salts, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the active compounds or pharmaceutically acceptable salts or derivatives thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients know and used in the art.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • the pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy.
  • Preferred routes of administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection.
  • the pharmaceutical composition of the invention can be manufactured by the skilled person by use of standard methods and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
  • each of the active ingredients depends on the nature and severity of the disease being treated, the exact mode of administration, form of administration and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, the below dosages for the compound and the anti-obesity compound are considered suitable.
  • the dosage of the compound is determined as the API (Active Pharmaceutical Ingredient), i.e. calculated as the free base.
  • the daily dosage of the compound may be administered in one or several doses, such as two, per day. In one embodiment, the daily dosage is administered in one dose.
  • the daily dosage of the anti-obesity compound is presently contemplated to be in the range of about 0.1-500 mg of active ingredient depending on the actual compound. More specific dosage intervals may be in the range of about 0.1-2 mg, about 1-10 mg, about 10-50 mg, about 25-100 mg, about 50-200 mg and about 100-500 mg daily.
  • the daily dosage of the anti-obesity compound may be administered in one or several doses, such as two, per day. In one embodiment, the daily dosage is administered in one dose.
  • an amount effective to achieve an end means the quantity of a component that is sufficient to yield an indicated therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this disclosure.
  • an amount effective to treat a movement disorder The specific effective amount will vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
  • to “treat” or “treating” encompasses, e.g., inducing inhibition, regression, or stasis of the disorder and/or disease.
  • “inhibition” of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.
  • “combination” means an assemblage of reagents for use in therapy either by simultaneous or contemporaneous administration.
  • Simultaneous administration refers to administration of an admixture (whether a true mixture, a suspension, an emulsion or other physical combination) of the Pridopidine and the Tetrabenazine.
  • the combination may be the admixture or separate containers of the Pridopidine and the Tetrabenazine that are combined just prior to administration.
  • Contemporaneous administration refers to the separate administration of the Pridopidine and the Tetrabenazine at the same time, or at times sufficiently close together that a synergistic activity or an activity that is additive or more than additive relative to the activity of either the Pridopidine or the Tetrabenazine alone is observed.
  • DOPAC is 3,4-Dihydroxyphenylacetic acid.
  • LMA Locomotor activity
  • TZ is Tetrabenazine
  • kit of parts comprising at least two separate unit dosage forms (A) and (B), wherein
  • (A) comprises Pridopidine, or a pharmaceutically acceptable salt thereof
  • (B) comprises Tetrabenazine, or a pharmaceutically acceptable salt thereof; and optionally
  • Pridopidine for use according to the invention and Tetrabenazine for use according to the invention may preferably be provided in a form that is suitable for administration in conjunction with the other. This is intended to include instances where one or the other of two formulations may be administered (optionally repeatedly) prior to, after, and/or at the same time as administration with the other component.
  • Pridopidine for use according to the invention and Tetrabenazine for use according to the invention may be administered in a combined form, or separately or separately and sequentially, wherein the sequential administration is close in time or remote in time.
  • This may in particular include that two formulations are administered (optionally repeatedly) sufficiently closely in time for there to be a beneficial effect for the patient, that is greater over the course of the treatment of the relevant condition than if either of the two formulations are administered (optionally repeatedly) alone, in the absence of the other formulation, over the same course of treatment. Determination of whether a combination provides a greater beneficial effect in respect of, and over the course of treatment of, a particular condition, will depend upon the condition to be treated or prevented, but may be achieved routinely by the person skilled in the art.
  • administered simultaneously and “administered at the same time as” include that individual doses of Pridopidine and Tetrabenazine are administered within 48 hours, e.g. 24 hours, of each other.
  • Bringing the two components into association with each other includes that components (A) and (B) may be provided as separate formulations (i.e. independently of one another), which are subsequently brought together for use in conjunction with each other in combination therapy; or packaged and presented together as separate components of a “combination pack” for use in conjunction with each other in combination therapy.
  • an article of manufacture comprising (A) a first pharmaceutical dosage form comprising Pridopidine, or a pharmaceutically acceptable salt thereof; and (B) a second pharmaceutical dosage form comprising Tetrabenazine, or a pharmaceutically acceptable salt thereof; wherein the article contains first and second pharmaceutical dosage forms.
  • the invention provides methods of treatment, prevention or alleviation of a hyperkinetic movement disorder in a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of Pridopidine, or a pharmaceutically acceptable salt thereof; in a combination therapy with Tetrabenazine, or a pharmaceutically acceptable salt thereof.
  • the hyperkinetic movement disorder may in particular be an involuntary movement disorder arising from Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.
  • the hyperkinetic movement disorder is an involuntary movement disorder arising from Huntington's disease.
  • Motor function is controlled by a complex circuitry connecting the cerebral cortex with subcortical structures including the basal ganglia and the thalamus.
  • One major pathway within this circuitry is the so called “indirect pathway” forming a closed feed-back loop connecting the cortex, the striatum, and the thalamus via a population of striatal GABA-ergic, medium spiny neurons expressing dopamine D2 type receptors.
  • This pathway functions as a negative regulator of movements, and is important for the suppression of excessive movements.
  • Dopamine modulates the indirect pathway by inhibitory dopamine D2 receptors in such a way that increased dopamine tone at these receptors leads to a reduced activity of the indirect pathway, and therefore a reduced ability to suppress movements.
  • a diminished dopamine tone leads to increased activity of the indirect pathway associated with stronger suppression of movements.
  • the direct pathway is a positive modulator of motor function, involved in the selection and enabling of voluntary movements.
  • Dopamine acting at D1 type receptors, stimulates the striatal GABA-ergic neurons in the direct pathway, thereby enhancing movements.
  • a reduction in dopamine tone at these D1 receptors leads to a reduced ability to perform voluntary movements.
  • the general reduction in dopamine transmission resulting from treatment with Tetrabenazine also reduces other dopamine dependent functions.
  • the dopamine tone at the direct pathway with striatal neurons expressing dopamine D1 receptors, is also reduced, leading to a weakening of the direct pathway and therefore to a reduced capacity to perform voluntary movements.
  • the dopamine depletion induced by Tetrabenazine is likely to impair dopamine dependent motivation and reward, which is hypothesised to underlie the pro-depressant adverse effects of Tetrabenazine.
  • Pridopidine is a pure antagonist at dopamine D2 receptors, with no agonist activity, it was expected that a therapeutic combination of Pridopidine and Tetrabenazine would lead to further reduced tone at dopamine D2 receptors, and therefore to a further reduction in overall locomotor activity, compared to treatment with Tetrabenazine only.
  • Tetrabenazine was given sc at 0.37, 0.64 and 1.1 mg/kg. LMA was recorded for 60 minutes after dosing. Thereafter rats were sacrificed and brains were collected. Analyses of brain tissues included DOPAC in the striatum, and Arc mRNA in the frontal cortex and striatum.
  • Tetrabenazine reduced locomotor activity.
  • FIG. 1 Tetrabenazine dose dependently inhibited spontaneous locomotor activity.
  • the 1.1 mg/kg Tetrabenazine dose group displayed a significant reduction to 40% of the vehicle control group mean (P ⁇ 0.01).
  • significant reductions (0 ⁇ 0.05) were seen both for the 1.1 and 0.37 mg/kg Tetrabenazine dose groups, whereas for the period 15-60 minutes post dosing significant effects (0 ⁇ 0.05) were observed at 0.64 and 1.1 mg/kg.
  • the reduction in locomotor activity reflects the decreased dopamine transmission caused by inhibition of VMAT2.
  • the increase in DOPAC is a neuronal marker of reduced tone at dopamine D2 receptors, due to the decreased dopamine transmission in rats treated with Tetrabenazine. See Table 1 and FIG. 1-2 .
  • the Arc increase in the striatum is most likely due to reduced tone at dopamine D2 receptors.
  • the Arc decrease in the frontal cortex is likely to be related to decreased dopamine transmission in the cortex leading to a reduced tone at dopamine D1 receptors.
  • Pridopidine was given sc at 11, 33 and 100 ⁇ mol/kg. Pridopidine displayed no inhibitory effect on spontaneous locomotor activity. A slight increase in locomotor activity was observed at the mid dose, 33 ⁇ mol/kg, over the full 60 minute recording period. See FIG. 4 . When the full hour of recording was examined, a significant increase in locomotor activity to 138% of the vehicle control group mean was observed for the 33 ⁇ mol/kg Pridopidine dose group (P ⁇ 0.05). During the initial 15 min a significant increase (P ⁇ 0.05) was seen for the 11 ⁇ mol/kg Pridopidine dose group, whereas for the period 15-60 minutes post dosing no significant effects were observed.
  • DOPAC dopamine D2 receptors
  • Pridopidine dose dependently increases striatal DOPAC, with statistically significant effects at all doses tested.
  • the increase in DOPAC is a neuronal marker of reduced tone at dopamine D2 receptors, due to dopamine D2 receptor antagonism exerted by Pridopidine. See FIG. 5 and Table 1.
  • the Arc increase in the striatum is most likely due to reduced tone at dopamine D2 receptors.
  • the Arc increase in the frontal cortex is likely to be related to increased dopamine transmission in the cortex leading to an increased tone at dopamine D1 receptors.
  • Haloperidol was given sc at 0.12, 0.37 and 1.1 mg/kg (See FIG. 7 ). In an additional experiment assessing effects at lower doses, 0.04, 0.12. 0.37 and 1.1 mg was given (See FIG. 302 ). Haloperidol displayed a dose-dependent inhibitory effect on spontaneous locomotor activity. Statistically significant effects were observed at 0.12 mg/kg and higher doses, but not at the lowest dose tested, 0.04 mg/kg.
  • the 0.37 and 1.1 mg/kg haloperidol dose groups displayed significant reductions to about 35% of the vehicle control group mean (P ⁇ 0.05).
  • significant reductions P ⁇ 0.05
  • the 0.37 and 1.1 mg/kg haloperidol dose groups were seen both for the 0.37 and 1.1 mg/kg haloperidol dose groups, whereas for the period 15-60 minutes post dosing a significant effect (P ⁇ 0.05) was observed for the 1.1 mg/kg dose group only.
  • Haloperidol dose dependently increased Arc mRNA in the striatum reaching 262% (P ⁇ 0.01), 331% (P ⁇ 0.001), 409% (P ⁇ 0.01), respectively, of the vehicle control group mean at the 0.12 mg/kg, 0.37 mg/kg and 1.1 mg/kg doses.
  • the Arc increase in the striatum is most likely due to reduced tone at dopamine D2 receptors. There was no significant effect of Haloperidol on cortical Arc gene expression. See FIG. 10 .
  • C vehicle control group; DOPAC, 3,4-dihydroxyphenylacetic acid; TC, Tetra-benazine control group *p ⁇ 0.05; **p ⁇ 0.01 ***p ⁇ 0.001 vs. vehicle control group; ⁇ p ⁇ 0.05; ⁇ p ⁇ 0.01; ⁇ p ⁇ 0.001 vs. Tetrabenazine control group.
  • Pridopidine was unique in that it did not inhibit locomotor activity. Another feature differentiating Pridopidine from Haloperidol or Tetrabenazine, is that it increased cortical Arc gene expression.
  • Tetrabenazine Pridopidine was given at 33 and 100 ⁇ mol/kg, combined with Tetrabenazine at 0.64 mg/kg. See FIG. 11 .
  • the locomotor recordings demonstrated that Pridopidine reversed the behavioural inhibition induced by Tetrabenazine.
  • the effects on striatal DOPAC were additive, i.e. coadministration of Pridopidine further increased striatal DOPAC.
  • Tetrabenazine 0.64 mg/kg was combined with either Pridopidine 33 mmol/kg or 100 mmol/kg
  • Tetrabenazine induced a significant increase in striatal DOPAC levels was seen compared with the vehicle-treated control group (p ⁇ 0.01; Table 1).
  • Pridopidine further increased DOPAC levels in striatum, reaching 155% of the Tetrabenazine control group mean at the 100 ⁇ mol/kg dose (p ⁇ 0.01). See Table 1 and FIG. 12 .
  • Pridopidine reversed the decrease in frontal cortex Arc induced by Tetrabenazine as shown in FIG. 13 . More specifically, Tetrabenazine had no significant effect on striatal Arc mRNA at the 0.64 mg/kg dose used in the interaction experiment. Pridopidine, when coadministered with Tetrabenazine, dose dependently increased striatal Arc, reaching 144% (P ⁇ 0.05) and 207% (P ⁇ 0.01), respectively, of the Tetrabenazine control group mean at the 33 ⁇ mol/kg, and the 100 ⁇ mol/kg doses of Pridopidine.
  • Tetrabenazine induced a significant decrease (P ⁇ 0.05) in frontal cortex Arc mRNA, which is in accordance with the trend towards a decrease of frontal cortex Arc mRNA at the 0.64 mg/kg dose observed in the dose response experiment with Tetrabenazine ( FIG. 3 ).
  • Pridopidine dose dependently reversed the decrease in frontal cortex Arc mRNA induced by Tetrabenazine.
  • Arc mRNA was increased to 125% (P ⁇ 0.05) and 193% (P ⁇ 0.05), respectively, of the Tetrabenazine control group mean
  • Haloperidol was given at 0.04 and 0.12 mg/kg, combined with Tetrabenazine at 0.64 mg/kg.
  • the locomotor recordings showed that Haloperidol further reduced locomotor activity in animals treated with Tetrabenazine. More specifically, the locomotor recording over the full hour demonstrated that haloperidol significantly (P ⁇ 0.01) reduced locomotor activity in rats treated with Tetrabenazine both at the 0.04 and 0.12 mg/kg doses, down to 51% and 41% of Tetrabenazine control group mean, respectively. For the first 15 min of recording this reducing effect was significant at both the 0.04 mg/kg (P ⁇ 0.01) and the 0.12 mg/kg (P ⁇ 0.05) doses, whereas for the 15-60 min period the reduction was significant for the 0.12 mg/kg dose only (P ⁇ 0.05). See FIG. 14 .
  • striatal DOPAC The effects on striatal DOPAC were additive, i.e. coadministration of Haloperidol with Tetrabenazine caused additional increases in striatal DOPAC.
  • Tetrabenazine 0.64 mg/kg was combined with haloperidol 0.04 mg/kg or 0.12 mg/kg
  • Tetrabenazine induced a significant increase in striatal DOPAC levels compared with the vehicle-treated control group (p ⁇ 0.001; Table 1).
  • Haloperidol further increased DOPAC levels in striatum, reaching 187% and 218% of the Tetrabenazine control group mean at the 0.04 mg/kg and 0.12 mg/kg doses, respectively (p ⁇ 0.001 for both doses). See Table 1 and FIG. 15 .
  • Haloperidol there was no significant effect of Haloperidol on cortical Arc gene expression in rats co-treated with Tetrabenazine. Haloperidol further increases striatal Arc in Tetrabenazine treated animals ( FIG. 16 ). Tetrabenazine had no significant effect on striatal Arc mRNA at the 0.64 mg/kg dose used in the interaction experiment. Haloperidol, when coadministered with Tetrabenazine, dose dependently increased striatal Arc, reaching 272% (P ⁇ 0.001) and 400% (P ⁇ 0.001), respectively, of the Tetrabenazine control group mean at the 0.04 mg/kg, and the 0.12 mg/kg doses of haloperidol.
  • Tetrabenazine tended to decrease frontal cortex Arc mRNA (P-0.08), which is in accordance with the trend towards a decrease of frontal cortex Arc mRNA at the 0.64 mg/kg dose observed in the dose response experiment with Tetrabenazine ( FIG. 3 ), and the significant decrease observed in the interaction experiment with Pridopidine and Tetrabenazine ( FIG. 13 ). There was no significant effect of haloperidol on frontal cortex Arc mRNA in Tetrabenazine treated animals.
  • Rats Male Sprague-Dawley rats from B&K Scanbur (Sollentuna, Sweden) (IBBS58), Charles River (Köln, Germany) (KR104, BS31) or Taconic (Ejby, Denmark) (BS85, BS81, KR219, TA284) were used. Rats weighed 160-180 g at the time of arrival. Rats weighed 220-260 g at the time of the locomotor and tissue neurochemistry studies. Animals were housed five animals per cage with lights on between 06:00 and 18:00. All experiments were carried out in accordance with Swedish animal protection legislation and with the approval of the local Animal Ethics Committee in Gothenburg.
  • Vehicle saline; NaCl 0.9% v/w
  • ACR16 tested at three doses (11; 33 and 100 ⁇ mol/kg).
  • the treatment groups consisted of Vehicle (Glucose 5.5% v/w) and Haloperidol tested at three doses (0.12; 0.37 and 1.1 ⁇ mol/kg).
  • the treatment groups consisted of Vehicle (Glucose 5.5% v/w) and Haloperidol tested at four doses (0.04; 0.12; 0.37 and 1.1 ⁇ mol/kg).
  • the treatment groups consisted of Vehicle 1:1 (saline; NaCl 0.9% v/w+5.5% glukos with a few drops of HAc)
  • the second group consisted of a single dose of Tetrabenazine (0.64 mg/kg)
  • the third and fourth groups consisted of NS30016 tested in two doses (33 and 100 ⁇ mol/kg together with Tetrabenazine in one dose (0.64 mg/kg).
  • the treatment groups consisted of Vehicle 1:1 (saline; NaCl 0.9% v/w+5.5% glukos with a few drops of HAc)
  • the second group consisted of a single dose of Tetrabenazine (0.64 mg/kg)
  • the third and fourth groups consisted of NS30016 tested in two doses (33 and 100 ⁇ mol/kg together with Tetrabenazine in one dose (0.64 mg/kg). No brain tissue was collected from this experiment.
  • the treatment groups consisted of Vehicle 1:1 (saline; NaCl 0.9% v/w+5.5% glukos with a few drops of HAc)
  • the second group consisted of a single dose of Tetrabenazine (0.64 mg/kg)
  • the third and fourth groups consisted of Haloperidol tested in two doses (0.04 and 0.12 mg/kg together with Tetrabenazine in one dose (0.64 mg/kg).
  • Behavioural activity is measured using eight Digiscan activity monitors (RXYZM (16) TAO, Omnitech Electronics, Columbus, Ohio, USA), connected to an Omnitech Digiscan analyzer and an Apple Macintosh computer equipped with a digital interface board (NB DIO-24, National Instruments, USA).
  • Each activity monitor consists of a quadratic metal frame equipped with photobeam sensors.
  • a rat is put in a transparent acrylic cage with matted black floor (W ⁇ L ⁇ H, 41 ⁇ 41 ⁇ 30 cm) which in turn is placed in the activity monitor.
  • Each activity monitor is equipped with three rows of infrared photobeam sensors, each row consisting of 16 sensors.
  • Each activity monitor is fitted in an identical sound and light attenuating box (W ⁇ L ⁇ H ⁇ 55 ⁇ 55 ⁇ 45) containing a weak house light and a fan.
  • the computer software is written using object oriented programming (LabVIEWTM, National instruments, Austin, Tex., USA).
  • Behavioural data from each activity monitor representing the position (horizontal center of gravity and vertical activity) of the animal at each time, are recorded at a sampling frequency of 25 Hz and collected using a custom written LABViewTM application.
  • the data from each recording session are stored and analyzed with respect to distance travelled.
  • Each behavioural recording session lasts 60 min, starting approximately 4 min after the injection of test compound.
  • the results are presented as counts/60 minutes, counts/45 minutes or counts/15 minutes, in arbitrary length units. Statistical comparisons are carried out using Student's t-test against the control group.
  • the rats are decapitated and their brains rapidly taken out and put on an ice-cold petri-dish.
  • PCA perchloric acid
  • EDTA ethylene-diamine-tetraacetic acid
  • GSH glutathione
  • alpha-methyl-dopamine (0.25 mM
  • a digital sonifier (Branson Digital Sonifier 250-D) was used to homogenise tissue from the striatum and limbic region. Cortex tissue was homogenised using an Ultra Turrax T25 homogeniser. All samples were centrifuged at 10.000 rpm for 10 minutes at +4° C. Cortex tissue was filtered in Munktell filter paper 5.5 cm quality 1F.
  • Tissue eluates were analysed with respect to tissue concentrations (ng/g tissue) of the monoamine transmitter substances (Norepinephrine (NA), dopamine (DA), 5-hydroxytryptamine (5-HT)) as well as their amine metabolites (normetanephrine (NM), 3-methoxytyramine (3-MT)) and acid metabolites (3,4-dihydroxyphenylalanine (DOPAC), 5-hydrocyindoleacetic acid (5-HIAA), homovanillic acid (HVA)) by HPLC separations and electrochemical detection (HPLC/EC).
  • AMDA 500 ⁇ g/ml internal standard
  • 5-HT and 5HIAA are dissolved in miliiQ water.
  • DA, NA, DOPAC, NM, 3-MT and HVA are dissolved in 0.01 M HCl.
  • 5-HT, 5-HIAA, NM and HVA are kept in fridge;
  • DA, DOPAC, NA and 3-MT are kept in freezer.
  • Standard solution for analyses containing standards diluted in homogenising solution to a concentration of 0.05 ⁇ g/ml is prepared daily.
  • the analytical method is based on two chromatographic separations dedicated for amines or acids.
  • Two chromatographic systems share a common auto injector with a 10-port valve and two sample loops for simultaneous injection on the two systems. Both systems are equipped with a reverse phase column (Luna C18(2), dp 3 ⁇ m, 50 ⁇ 2 mm i.d., Phenomenex) and electrochemical detection is accomplished at two potentials on glassy carbon electrodes (MF-1000, Bioanalytical Systems, Inc.).
  • the column effluent is passed via a T-connection to the detection cell or to a waste outlet. This is accomplished by two solenoid valves, which block either the waste or detector outlet. By preventing the chromatographic front from reaching the detector, better detection conditions are achieved.
  • the aqueous mobile phase (0.4 ml/min) for the acid system contains citric acid 14 mM, sodium citrate 10 mM, MeOH 15% (v/v) and EDTA 0.1 mM. Detection potentials relative to Ag/AgCl reference are 0.45 and 0.60V.
  • the aqueous ion pairing mobile phase (0.5 ml/min) for the amine system contains citric acid 5 mM, sodium citrate 10 mM, MeOH 9% (v/v), MeCN 10.5% v/v), decane sulfonic acid 0.45 mM, and EDTA 0.1 mM. Detection potentials relative to Ag/AgCl reference are 0.45 and 0.65V.
  • RNA is prepared by the guanidin isothiocyanate method (Chomczynski, 1987). RNA pellets are solved in MQ water and stored at ⁇ 80° C. The sample concentration is determined spectrophotometrically by a NanoDrop ND-1000. A quality indicator number and an integrity number of r-RNA are measured with an Experion (Bio-Rad) on random samples.
  • a two-step reversed transcription is performed by using a SuperScript III kit (Invitrogen). 1 ⁇ g of total RNA is reversed transcribed with 5 ⁇ l 2 ⁇ RT Reaction Mix, 1 ⁇ l RT Enzyme Mix, volume adjusted to 10 ⁇ l with DEPC-treated water. 1 U of E. coli RNase H is added. cDNA is diluted 40 times and stored at ⁇ 20° C.
  • Three sequences are amplified together in a triplex PCR-reaction.
  • 5 ⁇ l of the cDNA reaction is amplified in a 20 ⁇ l reaction mixture containing 10 ⁇ l Quanta buffer, 3.5 ⁇ l MQ, 0.15 ⁇ M of each primer and 0.1 ⁇ M of each probe.
  • Real-time PCR is measured on CFX96 (Biorad) using the following settings for all genes: 3 min pre-incubation at 95 degrees C. followed by 40 cycles of denaturation at 95 degrees C. for 15 s, annealing and elongation at 60 degrees C. for 1 minut.
  • Reference genes are HPRT and cyclophilin.
  • the primer and probe sequences are as follows for measuring of arc:
  • Cyclophilin A (Accession Number M19533)
  • PCR products are confirmed by agarose gel electroforesis (2%) PCR products are purified with PCR purification kit from Qiagen (Valencia, Calif., USA). All genes are sequenced at MWG, Germany. The amounts of gene of interests are normalised with the two reference genes HPRT and cyclophilin A.
  • Reversed transcription is performed by using a ThermoScript kit (Invitrogen). 1 ⁇ g of total RNA is reverse transcribed with 25 ⁇ mol oligo (dT), 62.5 ng random hexamers, 7.5U Thermoscript RT, 100 RNaseOut, 2 ⁇ l 5 ⁇ cDNA Synthesis buffer, 1 mM dNTP, 0.05 M DTT, adjust volume to 10 ⁇ l with DEPC-treated water. Then cDNA is diluted 40 times and stored at ⁇ 20° C.
  • RNA was prepared by the guanidine isothiocyanate method (Schaefer 1984). RNA pellets were dissolved in ultrapure water and stored at ⁇ 80° C. RNA concentration was determined spectrophotometrically using a NanoDrop ND-1000 (Thermo Scientific, Waltham, Mass., USA). A quality indicator number and an integrity number of ribosomal RNA were determined for random samples using an Experion electrophoresis system (Bio-Rad Laboratories, Hercules, Calif., USA). Reverse transcription was performed using a SuperScript III kit or a ThermoScript kit (both from Life Technologies Europe BV, Sweden).
  • RNA was reverse-transcribed with 5 ⁇ l 2 ⁇ RT Reaction Mix and 1 ⁇ l RT Enzyme Mix (SuperScript III kit); for studies with Pridopidine and haloperidol, 1 ⁇ g RNA was reverse-transcribed using a ThermoScript kit with 25 pmol oligo(dT), 62.5 ng random hexamers, 7.5 U ThermoScript reverse transcriptase, 10 U RNaseOut, 2 ⁇ l 5 ⁇ cDNA Synthesis Buffer, 1 mM dNTPs and 0.05 M dithiothreitol. In all studies, cDNA volume was adjusted to 10 ⁇ l with diethylpyrocarbonate-treated water. Escherichia coli RNase H (1 U) was added, then cDNA was diluted 40 times and stored at ⁇ 20° C.
  • cDNA of Arc and two reference genes hypoxanthine-guanine phosphoribosyltransferase (HART) and cyclophilin A
  • HART hypoxanthine-guanine phosphoribosyltransferase
  • cyclophilin A was amplified by real-time PCR in either a triplex reaction (Tetrabenazine studies) or three singleplex reactions (studies with Pridopidine and haloperidol).
  • 5 ⁇ l cDNA was amplified in a 20 ⁇ l reaction mixture containing 10 ⁇ l Quanta buffer (Quanta BioSciences Inc., Gaithersburg, Md., USA), 3.5 ⁇ l ultrapure water, 0.15 ⁇ M of each primer and 0.1 ⁇ M of each probe (the primer and probe sequences used are detailed in Table 3).
  • Products of the triplex real-time PCR were detected on a CFX96 system (Bio-Rad Laboratories, Hercules, Calif., USA) using the following settings for all genes: 3 minutes pre-incubation at 95° C., followed by 40 cycles of denaturation at 95° C. for 15 seconds, and annealing and elongation at 60° C. for 1 minute.
  • CFX96 system Bio-Rad Laboratories, Hercules, Calif., USA
  • 0.7 ⁇ l cDNA was amplified in a 25 ⁇ l reaction mixture containing lx PCR buffer, 0.2 mM dNTPs, 3.7 mM MgCl 2 , 0.15 mM SYBR Green, 0.4 ⁇ M of primer (Table 2) and 1 U Taq polymerase.
  • Cyclophilin A (Accession Number M19533)
  • Tetrabenazine produced a dose-dependent decrease in striatal dopamine levels, which was not affected by co-administration of Pridopidine or haloperidol. Moreover, Tetrabenazine produced a dose-dependent increase in frontal cortex Arc mRNA levels. This effect was counteracted in a dose-dependent manner by Pridopidine, but not by haloperidol.
  • the pharmacological effect of Pridopidine at dopamine D2 receptors was present also when co-administered with Tetrabenazine.
  • the neurochemical analysis demonstrated that all three compounds tested produced a dose dependent increase in striatal DOPAC, reaching around 250-300% of control levels at the top doses applied, in line with previous results.
  • An increase in striatal DOPAC is a common feature of dopamine D2 antagonists, as well as compounds in general producing a reduced tone at central dopamine D2 receptors, including partial agonists with low intrinsic activity, and monoamine depleting drugs (Jordan, 2004; Roffler-Tarlov 1971).
  • the increase seen in striatal DOPAC thus represents a core pharmacological effect of each of the compounds tested.
  • both haloperidol and Pridopidine produced an additional increase in striatal DOPAC, when co-administered with Tetrabenazine. This strongly suggests that the primary effect of Pridopidine and haloperidol was still present in partially monoamine depleted rats. Furthermore, despite the fact that Pridopidine reversed the locomotor-suppressant effect of Tetrabenazine when they were co-administered, the decrease in tissue levels of dopamine induced as a signature effect of Tetrabenazine was unaffected by Pridopidine, suggesting that it did not abolish the pharmacological effects of Tetrabenazine as such.
  • the increased Arc mRNA in cortex by Pridopidine co-treatment may help to explain reversal of Tetrabenazine induced locomotor depression.
  • Arc mRNA was measured in the frontal cortex and the striatum.
  • Arc is an early gene associated with synaptic activation and NMDA receptor signalling, and has previously been reported to increase in the striatum in response to several dopamine D2 antagonists, as well as dopaminergic stabilizers.
  • Tetrabenazine induced a significant increase in striatal Arc.
  • Tetrabenazine reduced Arc gene expression dose dependently, with significant effects at and above the dose used for the interaction experiments.
  • the dose response studies of Pridopidine and haloperidol demonstrated a dose dependent increase in frontal cortex Arc gene expression by Pridopidine, but no effects of haloperidol.
  • the ability of Pridopidine to increase frontal cortex Arc gene expression was also evident in Tetrabenazine treated rats.
  • this pharmacological effect which distinguishes Pridopidine from haloperidol and other classic dopamine D2 antagonists, was maintained upon partial monoamine depletion.
  • Tetrabenazine induced a dose dependent reduction in striatal dopamine.
  • Tetrabenazine reduced striatal dopamine significantly, reaching approximately 50% of vehicle control group mean, throughout the studies performed.
  • Pridopidine and haloperidol both produced smaller decreases in striatal dopamine, at the highest doses tested.
  • the effect of Tetrabenazine on striatal dopamine was essentially unaffected by cotreatment with Pridopidine or haloperidol.
  • Pridopidine reversed the behavioural inhibition induced by the monoamine depleting compound Tetrabenazine, while retaining Pridopidine's core neurochemical effects related to dopamine D2 receptor antagonism.
  • the locomotor depressant effects of Tetrabenazine are alleviated by Pridopidine, despite that the tone at striatal dopamine D2 receptor is further reduced when Pridopidine is administered in addition to Tetrabenazine.
  • Pridopidine also reversed the decrease in frontal cortex Arc gene expression induced by Tetrabenazine. Tentatively, this reflects an activation of cortical neuronal activity that might contribute to the locomotor stimulatory effects of Pridopidine in partially monamine depleted, hypoactive rats.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US13/856,254 2012-04-04 2013-04-03 Pharmaceutical compositions for combination therapy Abandoned US20130267552A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/856,254 US20130267552A1 (en) 2012-04-04 2013-04-03 Pharmaceutical compositions for combination therapy
US15/612,779 US20170266170A1 (en) 2012-04-04 2017-06-02 Pharmaceutical compositions for combination therapy
US16/203,182 US11207308B2 (en) 2012-04-04 2018-11-28 Pharmaceutical compositions for combination therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261620203P 2012-04-04 2012-04-04
US201261625192P 2012-04-17 2012-04-17
US201361783730P 2013-03-14 2013-03-14
US13/856,254 US20130267552A1 (en) 2012-04-04 2013-04-03 Pharmaceutical compositions for combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/612,779 Continuation US20170266170A1 (en) 2012-04-04 2017-06-02 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
US20130267552A1 true US20130267552A1 (en) 2013-10-10

Family

ID=49292803

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/856,254 Abandoned US20130267552A1 (en) 2012-04-04 2013-04-03 Pharmaceutical compositions for combination therapy
US15/612,779 Abandoned US20170266170A1 (en) 2012-04-04 2017-06-02 Pharmaceutical compositions for combination therapy
US16/203,182 Active US11207308B2 (en) 2012-04-04 2018-11-28 Pharmaceutical compositions for combination therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/612,779 Abandoned US20170266170A1 (en) 2012-04-04 2017-06-02 Pharmaceutical compositions for combination therapy
US16/203,182 Active US11207308B2 (en) 2012-04-04 2018-11-28 Pharmaceutical compositions for combination therapy

Country Status (16)

Country Link
US (3) US20130267552A1 (zh)
EP (1) EP2844346B1 (zh)
JP (1) JP6177875B2 (zh)
KR (1) KR20150013476A (zh)
CN (1) CN104470585A (zh)
AU (1) AU2013243461A1 (zh)
BR (1) BR112014024672A8 (zh)
CA (1) CA2869145A1 (zh)
EA (1) EA027748B1 (zh)
ES (1) ES2776678T3 (zh)
HK (1) HK1206297A1 (zh)
IL (1) IL234831B (zh)
MX (1) MX2014011971A (zh)
NZ (1) NZ630560A (zh)
WO (1) WO2013152105A1 (zh)
ZA (1) ZA201407726B (zh)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105736A1 (en) * 2007-04-12 2010-04-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
WO2015112601A1 (en) 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016003919A1 (en) 2014-06-30 2016-01-07 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CN106456651A (zh) * 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US10047049B2 (en) 2015-07-22 2018-08-14 Teva Pharmaceuticals International Gmbh Process for preparing pridopidine
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11000519B2 (en) 2017-09-08 2021-05-11 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11234973B2 (en) 2017-01-20 2022-02-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile X syndrome
EP4005570A1 (en) 2016-09-16 2022-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US11406625B2 (en) 2017-08-14 2022-08-09 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
WO2019016357A1 (en) 2017-07-20 2019-01-24 Neurolixis USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
EP3740401A1 (de) * 2018-01-17 2020-11-25 Hirschmann Car Communication Gmbh Ein von einem empfangssystem abgesetztes lte-modul
JP7386544B2 (ja) * 2018-04-25 2023-11-27 シンケイ セラピューティクス インコーポレイテッド テトラベナジン経皮送達デバイス

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (zh) 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
US4048314A (en) 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
US4267328A (en) 1978-08-01 1981-05-12 Synthelabo 1-Phenylpiperazines
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
EP0094159B1 (en) 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
DE3306964A1 (de) 1983-02-28 1984-09-06 Boehringer Ingelheim KG, 6507 Ingelheim Neues n-arylpiperazin und verfahren zu seiner herstellung
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
AU653837B2 (en) 1991-04-17 1994-10-13 Pharmacia & Upjohn Company Substituted phenylazacycloalkanes as CNS agents
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
IL112099A (en) 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
AU6470096A (en) 1995-07-19 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
HUP9904335A3 (en) 1996-07-22 2001-07-30 Daiichi Asubio Pharma Co Ltd Arylpiperidinol and arylpiperidine derivatives and drugs containing the same
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
JP2001526643A (ja) 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
SI0994872T1 (zh) 1997-06-10 2001-08-31 Synthon Bv
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
WO1999007667A1 (fr) * 1997-08-07 1999-02-18 Fujimoto Brothers Co., Ltd. Nouveaux derives d'ethylamine
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US6121259A (en) 1998-11-23 2000-09-19 Sepracor Inc. Olanzapine-N-oxide compositions and methods
ATE316076T1 (de) 1999-06-22 2006-02-15 Neurosearch As Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
WO2001008678A1 (en) 1999-07-30 2001-02-08 University Of Kentucky Research Foundation Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2002005819A1 (en) 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
DE60205727T2 (de) 2001-01-23 2006-06-29 Eli Lilly And Co., Indianapolis Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
AU2005251906B2 (en) 2004-06-08 2011-03-31 Nsab, Filial Af Neurosearch Sweden Ab, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2582447C (en) 2004-10-01 2012-04-17 Merck & Co., Inc. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
JP2008515952A (ja) 2004-10-13 2008-05-15 ニューロサーチ スウェーデン アクチボラゲット ４−（３−スルホニルフェニル）−ピペリジンの合成方法
DE602006004363D1 (de) 2005-08-22 2009-01-29 Solvay Pharm Bv N-oxide als prodrugs von piperazin- und piperidinderivaten
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
JP2009518337A (ja) 2005-12-07 2009-05-07 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン
CN101432279A (zh) 2006-05-02 2009-05-13 索尔瓦药物有限公司 吡啶基甲基哌嗪和吡啶基甲基哌啶衍生物的n-氧化物
US20090318500A1 (en) 2006-05-05 2009-12-24 Astex Therapeutics Limited 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
US20100204258A1 (en) * 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
RU2470013C2 (ru) 2007-04-12 2012-12-20 НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
MX2011005096A (es) 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
BRPI1010024A2 (pt) * 2009-06-05 2019-09-24 Link Medicine Corp derivados de aminopirrolidinona e uso dos mesmos
WO2011014003A2 (en) 2009-07-29 2011-02-03 Green Cross Corporation (+)-3-hydroxymorphinan derivatives as neuroprotectants
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2011107593A1 (en) 2010-03-05 2011-09-09 Dsm Ip Assets B.V. Process for the production of an uhmwpe article
EP2576552A4 (en) * 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc BENZOQUINOLONE INHIBITORS OF VMAT2
US20130216856A1 (en) 2010-07-02 2013-08-22 Marco Burtchen Mechanical component and method of surface hardening
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2013034622A1 (en) 2011-09-07 2013-03-14 Neurosearch A/S Polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AANS - Movement Disorders, http://www.aans.org/patient%20information/conditions%20and%20treatments/movement%20disorders.aspx, accessed 5/19/2015, published 2013 *
Clinical Trials (https://clinicaltrials.gov/archive/NCT00665223/2010_02_03, published 2/3/2010, accessed 2/28/2017) *
de Yebenes et al (Lancet Neurol 2011; 10: 1049-57). *
Dyhring et al. (European Journal of Pharmacology 628 (2010) 19-26) *
FDA (http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932.pdf, accessed 6/7/2016, published 2005) *
H. Ponten et al. (European Journal of Pharmacology 644 (2010) 88–95) *
LaVonne Goodman M.D. (http://hddrugworks.org/index.php?option=com_content&task=view&id=277, accessed 5/19/2015, published 2/16/2010) *
Paula Diana (Neuropsychiatric Disease and Treatment 2007:3(5) 545-551) *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US20100105736A1 (en) * 2007-04-12 2010-04-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US9139525B2 (en) 2007-04-12 2015-09-22 Teva Pharmaceuticals International Gmbh N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9814706B2 (en) 2011-12-08 2017-11-14 Teva Pharmaceuticals International Gmbh Hydrobromide salt of pridopidine
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US20190209542A1 (en) * 2014-01-22 2019-07-11 Prilenia Therapeutics Development Ltd. Modified release formulations of pridopidine
KR20160125385A (ko) * 2014-01-22 2016-10-31 테바 파마슈티컬스 인터내셔널 게엠베하 프리도피딘의 변형된 방출 제제
IL280485B2 (en) * 2014-01-22 2023-05-01 Prilenia Neurotherapeutics Ltd Sustained-release pridopidine preparations
KR102479759B1 (ko) * 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
EP4049657A1 (en) 2014-01-22 2022-08-31 Prilenia Neurotherapeutics Ltd. Modified release formulations of pridopidine
WO2015112601A1 (en) 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
IL280485A (en) * 2014-01-22 2021-03-01 Prilenia Neurotherapeutics Ltd Sustained-release pridopidine preparations
CN106456651A (zh) * 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
US10130621B2 (en) 2014-06-30 2018-11-20 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
WO2016003919A1 (en) 2014-06-30 2016-01-07 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
US10406145B2 (en) 2014-06-30 2019-09-10 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
EP4049998A1 (en) 2014-06-30 2022-08-31 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
US11141412B2 (en) 2014-06-30 2021-10-12 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10047049B2 (en) 2015-07-22 2018-08-14 Teva Pharmaceuticals International Gmbh Process for preparing pridopidine
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
EP4005570A1 (en) 2016-09-16 2022-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US11234973B2 (en) 2017-01-20 2022-02-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile X syndrome
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
US11406625B2 (en) 2017-08-14 2022-08-09 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
US11452694B2 (en) 2017-08-30 2022-09-27 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE
US11000519B2 (en) 2017-09-08 2021-05-11 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Also Published As

Publication number Publication date
EP2844346A4 (en) 2015-11-18
EP2844346B1 (en) 2020-01-01
IL234831B (en) 2020-10-29
BR112014024672A2 (zh) 2017-06-20
NZ630560A (en) 2016-11-25
BR112014024672A8 (pt) 2018-04-03
EA201491819A1 (ru) 2015-04-30
WO2013152105A1 (en) 2013-10-10
EA027748B1 (ru) 2017-08-31
JP6177875B2 (ja) 2017-08-09
HK1206297A1 (zh) 2016-01-08
EP2844346A1 (en) 2015-03-11
ZA201407726B (en) 2016-05-25
US11207308B2 (en) 2021-12-28
AU2013243461A1 (en) 2014-11-06
MX2014011971A (es) 2015-01-16
JP2015515475A (ja) 2015-05-28
ES2776678T3 (es) 2020-07-31
CA2869145A1 (en) 2013-10-10
IL234831A0 (en) 2014-12-31
US20200000785A1 (en) 2020-01-02
US20170266170A1 (en) 2017-09-21
KR20150013476A (ko) 2015-02-05
CN104470585A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
US11207308B2 (en) Pharmaceutical compositions for combination therapy
JP2024037891A (ja) 黒色腫の治療のための組合せ医薬
CN106456629A (zh) 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
JP2023514568A (ja) ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ
CA2617274A1 (en) Use of hdac inhibitors for the treatment of myeloma
US9254274B2 (en) Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
US7915262B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
AU2018293718A1 (en) Combination comprising decanoic acid for the treatment of epilepsy
WO2008090334A1 (en) Serotonin receptor antagonists for treating arthritis
TW201345528A (zh) 用於組合療法之醫藥組合物
EP3849310A1 (en) Combination cancer therapies
US20160151316A1 (en) Method of treating tourette's disorder with gaba-aminotransferase inactivators
Waters et al. Co-administration of the dopaminergic stabilizer pridopidine and tetrabenazine in rats
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
RU2779202C2 (ru) Комбинация, содержащая декановую кислоту, для лечения эпилепсии
AU2016277929A1 (en) Combination therapy using belinostat and pralatrexate to treat lymphoma
WO2007144421A1 (en) Combination preparations comprising slv308 and a l-dopa
AEs et al. GABAPENTIN (continued)
Works et al. increased gastric acid secretion, weight loss
WO2017098237A1 (en) (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth.
SA07280317B1 (ar) مستحضرات توليفية تشتمل على slv308 وl – dopa

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUROSEARCH A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WATERS, ROSS NICHOLAS;HOLM WATERS, EVA SUSANNA;REEL/FRAME:030473/0098

Effective date: 20130417

Owner name: IVAX INTERNATIONAL GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUROSEARCH A/S;REEL/FRAME:030473/0125

Effective date: 20130409

AS Assignment

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH, SWITZERLA

Free format text: CHANGE OF NAME;ASSIGNOR:IVAX INTERNATIONAL GMBH;REEL/FRAME:035318/0079

Effective date: 20150223

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION